A carregar...
Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
OBJECTIVE: Hydroxychloroquine (HCQ) was not approved in Japan until 2015, and its therapeutic potential has not been explored in depth. We evaluated the additional therapeutic effect of HCQ in Japanese patients with systemic lupus erythematosus (SLE) on maintenance therapy. METHODS: Patients with SL...
Na minha lista:
| Publicado no: | Intern Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Japanese Society of Internal Medicine
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543229/ https://ncbi.nlm.nih.gov/pubmed/30626831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1999-18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|